PARP inhibitor
Prioritizing PARylation in DNA Damage and Repair
The Scientist Staff | Apr 1, 2024 | 2 min read
Measuring cellular poly ADP-ribosylation can unlock new anticancer strategies and approaches.
Therapeutic Development for Breast Cancer and Beyond
BPS Bioscience | Apr 5, 2023 | 1 min read
Scientists develop anticancer drugs that target PARP proteins involved in the DNA damage response.
Setting Better Traps for PARP Inhibitors
The Scientist and BPS Bioscience | Apr 19, 2022 | 4 min read
An innovative assay permits researchers to screen for small molecule PARP inhibitors that trap the enzyme on DNA and selectively execute cancer cells.
DNA Damage Makes Zebrafish Sleepy
Sophie Fessl, PhD | Nov 18, 2021 | 4 min read
Buildup of a DNA-repair protein in brain cells spurs shut-eye in the fish, a study finds, and similar results in mice suggest the mechanism is widespread in animals.
GlaxoSmithKline to Acquire Cancer Biotech TESARO for $5.1 Billion
Carolyn Wilke | Dec 3, 2018 | 1 min read
The purchase aims to build GSK’s oncology pipeline.
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018 | 9 min read
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.